Muscular Dystrophies clinical trials at UC Irvine
2 in progress, 1 open to eligible people
Showing trials for
AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
open to eligible people ages 18-65
The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)
Irvine 5359777, California 5332921 and other locations
Defining Endpoints in Becker Muscular Dystrophy
Sorry, in progress, not accepting new patients
This is a 24-month, observational study of 50 participants with Becker muscular dystrophy (BMD)
Orange 5379513, California 5332921 and other locations
Our lead scientists for Muscular Dystrophies research studies include Tahseen Mozaffar, MD.
Last updated: